Travere Therapeutics (NASDAQ:TVTX) Insider William Rote Sells 2,763 Shares of Stock

Travere Therapeutics, Inc. (NASDAQ:TVTX) insider William Rote sold 2,763 shares of the company’s stock in a transaction that occurred on Wednesday, May 6th. The shares were sold at an average price of $43.95, for a total value of $121,433.85. Following the sale, the insider directly owned 115,474 shares in the company, valued at approximately $5,075,082.30. This represents a 2.34% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Travere Therapeutics Stock Performance

TVTX stock opened at $44.70 on Thursday. The company has a current ratio of 3.13, a quick ratio of 2.70 and a debt-to-equity ratio of 3.16. The firm has a market cap of $4.16 billion, a P/E ratio of -194.33 and a beta of 1.13. Travere Therapeutics, Inc. has a 12-month low of $13.88 and a 12-month high of $48.61. The stock’s 50 day simple moving average is $32.59 and its 200 day simple moving average is $32.83.

Travere Therapeutics (NASDAQ:TVTX) last posted its quarterly earnings results on Monday, May 4th. The company reported $0.05 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.24) by $0.29. The business had revenue of $127.20 million for the quarter, compared to analyst estimates of $136.23 million. Travere Therapeutics had a negative return on equity of 26.16% and a negative net margin of 4.00%.The business’s revenue was up 55.6% compared to the same quarter last year. During the same period in the prior year, the company posted ($0.47) EPS. As a group, equities research analysts predict that Travere Therapeutics, Inc. will post -0.16 EPS for the current year.

Wall Street Analyst Weigh In

Several brokerages have weighed in on TVTX. Wells Fargo & Company increased their target price on Travere Therapeutics from $40.00 to $50.00 and gave the stock an “overweight” rating in a research report on Wednesday. Canaccord Genuity Group increased their target price on Travere Therapeutics from $47.00 to $56.00 and gave the stock a “buy” rating in a research report on Tuesday, April 14th. JPMorgan Chase & Co. dropped their target price on Travere Therapeutics from $44.00 to $41.00 and set an “overweight” rating on the stock in a research report on Wednesday, March 25th. Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Travere Therapeutics in a research report on Wednesday, January 21st. Finally, Wedbush increased their target price on Travere Therapeutics from $53.00 to $55.00 and gave the stock an “outperform” rating in a research report on Tuesday. Ten equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, Travere Therapeutics has a consensus rating of “Moderate Buy” and an average target price of $47.83.

Trending Headlines about Travere Therapeutics

Here are the key news stories impacting Travere Therapeutics this week:

• Positive Sentiment: TD Cowen raised its price target to $60 and keeps a “buy” rating — a large upside from the recent price that supports buying interest and likely helped lift the stock. Article Title
• Positive Sentiment: Wells Fargo raised its price target to $50 and moved to an “overweight” rating — another bullish analyst signal adding demand. Article Title
• Positive Sentiment: Recent Q1 results (reported May 4) showed an EPS beat and ~55.6% revenue growth year?over?year, providing fundamental support for the analyst upgrades and investor optimism. No link
• Neutral Sentiment: Travere priced an upsized $475.0M offering of 0.50% convertible senior notes due 2032 (up from $400M). This extends maturity and raises liquidity but carries potential future dilution if converted; the deal closes subject to conditions on May 11. Article Title
• Neutral Sentiment: HC Wainwright slightly trimmed long?term EPS forecasts (FY2027–FY2030) but maintains a “Buy” rating and a $57 target — small model tweaks that didn’t remove analyst support. No link
• Neutral Sentiment: Transcript of the Q1 2026 earnings call is available for detail review if you want management color on growth drivers and use of proceeds from the notes offering. Earnings Call Transcript
• Negative Sentiment: Multiple insiders — including the CEO, several directors and executives — sold shares recently (large transactions disclosed via Form 4s). While the company says many sales were executed under pre?arranged Rule 10b5?1 plans and to cover tax withholding on awards, the volume (notably the CEO’s 22,500?share sale) can create short?term selling pressure or investor concern. Example SEC filing: CEO Form 4

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. Emerald Advisers LLC boosted its stake in Travere Therapeutics by 2.6% during the third quarter. Emerald Advisers LLC now owns 2,146,767 shares of the company’s stock valued at $51,308,000 after buying an additional 55,407 shares in the last quarter. Palisades Investment Partners LLC acquired a new position in shares of Travere Therapeutics in the 4th quarter valued at $5,264,000. Essex Investment Management Co. LLC purchased a new stake in Travere Therapeutics in the 3rd quarter worth about $3,872,000. Lisanti Capital Growth LLC purchased a new stake in Travere Therapeutics in the 3rd quarter worth about $3,095,000. Finally, Apis Capital Advisors LLC purchased a new stake in Travere Therapeutics in the 3rd quarter worth about $3,967,000.

About Travere Therapeutics

Travere Therapeutics, Inc (NASDAQ: TVTX) is a biopharmaceutical company headquartered in San Diego, California, dedicated to the development and commercialization of therapies for rare kidney and genetic disorders. The company’s mission is to address unmet needs in conditions with limited treatment options by focusing on diseases that affect small patient populations. Travere combines research, development and commercial capabilities to bring innovative medicines to market.

The company’s lead product is sparsentan, a dual endothelin angiotensin receptor antagonist that has received accelerated approval from the U.S.